NTLA-2002 in Adults With Hereditary Angioedema (HAE)
← catalyst calendarSponsored by Intellia Therapeutics (industry) · NTLA — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
37actual
Sites
9
Countries
Australia, France, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-10 | actual | When the study began enrolling |
| Primary completion | 2024-04-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hereditary Angioedema
Interventions
- Biological: Biological NTLA-2002
- Other: Normal Saline IV Administration
Primary outcomes
what the primary-completion date above is the date OFSafety and tolerability of NTLA-2002 as determined by adverse events (AEs) and dose limiting toxicities (DLTs)
measured From NTLA-2002 infusion up to week 104 post-infusion
Number of HAE attacks per month (Weeks 1-16)
measured From study drug infusion up to week 16 post-infusion
Publications
- PMID 39445704 — linked by the registry
- PMID 38294975 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NTLA's whole pipeline · Catalyst calendar · Every registered study · What changed